Colorectal Cancer

>

Latest News

Expert Commentary on the Product Profile of Fruquintinib in Metastatic CRC
Expert Commentary on the Product Profile of Fruquintinib in Metastatic CRC

July 11th 2024

Jagoda Misniakiewicz, PharmD, discussed implementing fruquintinib into clinical practice and how it's mechanism of action compares with others in the space.

The EA2201 trial assessed nivolumab plus ipilimumab and short-course radiation therapy for patients with locally advanced rectal cancer.
Nivolumab/Ipilimumab Plus RT Shows Promise in Locally Advanced Rectal Cancer

July 1st 2024

HRQOL data from the CheckMate 8HW trial may further support frontline nivolumab/ipilimumab for those with MSI-H or dMMR metastatic colorectal cancer.
Nivolumab Combo Improves HRQOL Vs Chemo in MSI-H/dMMR Metastatic CRC

June 28th 2024

Data from FRESCO-2 support the approval of fruquintinib for those with previously treated metastatic colorectal cancer in the European Union.
European Commission Approves Fruquintinib in Pretreated Metastatic CRC

June 24th 2024

Data from the colorectal cancer cohort of the KRYSTAL-1 trial support the accelerated approval of adagrasib/cetuximab in KRAS G12C–mutated disease.
FDA Approves Adagrasib/Cetuximab in KRAS G12C-Mutated CRC

June 21st 2024

Video Series
Video Interviews
Podcasts
Oncology pharmacist Jagoda Misniakiewicz, PharmD, discusses the potential efficacy and safety profile of fruquintinib in patients with metastatic CRC.
Surgical oncologists from Cleveland Clinic discuss the National Accreditation Program for Rectal Cancer and its aim to improve patient outcomes.
Gregory Charak, MD, discusses how modalities like laparoscopic surgery and neoadjuvant immunotherapy may benefit patients with colorectal cancer.
New studies and treatment options prove to be effective in treating metastatic CRC, notes Joleen Hubbard, MD.
Personalized therapy tailored for mutation status is something to expect in the coming years for colorectal cancer treatment, notes Tanios S. Bekaii-Saab, MD.
New treatment updates could help find more patient subtypes to target and treat in the world of CRC.
Arvind N. Dasari, MD, and Cathy Eng, MD, discuss clinical trial data that may support the FDA approval of fruquintinib in metastatic colorectal cancer, and how it may impact the standard of care.
Lead author Ibrahim Halil Sahin, MD, spoke with CancerNetwork® about his work investigating postoperative circulating tumor DNA dynamics in early-stage colon cancer as part of the CIRCULATE-US trial published in the journal ONCOLOGY®.
Between the Lines™ Podcast: ctDNA as a Biomarker of Progression in Colorectal Cancer

More News